Skip to content

Aqilion receives SEK 100 million through conversion of outstanding warrants

In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and two (2) warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which raised an additional SEK 100 million for the company. The issue was carried out to fund the restructuring of Aqilion’s strategy and organization, as well as the development of current and new pharmaceutical projects in the pipeline.

“It is extremely rewarding that the entire issue of units is completed and fully subscribed. It means that, with the support of Aqilion’s owners and the Board of Directors, we can continue to develop the project portfolio and increase the value of the company. On behalf of the entire team, I am both grateful and proud to be entrusted with this mission. With a new organization and funding lined up, we have created the optimum conditions to focus on efficiently developing our business model and our pharmaceutical projects,” says Sarah Fredriksson, CEO of Aqilion.

Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are particularly interesting. Aqilion has its headquarters in Helsingborg, Sweden. Please visit

Download press release in PDF-format »